Cover Image
市場調查報告書

輸尿管癌症:開發中產品分析

Ureter Cancer - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 247802
出版日期 內容資訊 英文 131 Pages
訂單完成後即時交付
價格
Back to Top
輸尿管癌症:開發中產品分析 Ureter Cancer - Pipeline Review, H1 2017
出版日期: 2017年05月16日 內容資訊: 英文 131 Pages
簡介

輸尿管癌症的症狀有尿道出血或血尿、膿、鼠蹊部的淋巴節腫大等。危險因素有吸煙。治療方法有手術、化療、放射線療法等。

本報告提供輸尿管癌症的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

輸尿管癌症 概要

治療藥的開發

  • 開發中產品;概要
  • 各企業的開發中產品
  • 各大學/研究機關的開發中產品
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Altor BioScience Corp
  • Eisai
  • Exelixis Inc
  • GlaxoSmithKline Plc
  • MedImmune LLC
  • Merck & Co Inc

藥物簡介

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9286IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ureter Cancer - Pipeline Review, H1 2017, provides an overview of the Ureter Cancer (Oncology) pipeline landscape.

Ureter cancer or ureteral cancer is cancer of the ureter. Symptoms and signs of urethral cancer include bleeding from the urethra or blood in the urine, discharge from the urethra and enlarged lymph nodes in the groin area. Risk factors include smoking. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ureter Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Ureter Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ureter Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ureter Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 3, 2 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Ureter Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ureter Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Ureter Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ureter Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ureter Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ureter Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ureter Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ureter Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Ureter Cancer - Overview
    • Ureter Cancer - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Ureter Cancer - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Ureter Cancer - Companies Involved in Therapeutics Development
    • Altor BioScience Corp
    • Eisai Co Ltd
    • Exelixis Inc
    • GlaxoSmithKline Plc
    • MedImmune LLC
    • Merck & Co Inc
  • Ureter Cancer - Drug Profiles
    • ALT-801 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cabozantinib s-malate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • durvalumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • durvalumab + tremelimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eribulin mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-3326595 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pembrolizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PGV-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Ureter Cancer - Product Development Milestones
    • Featured News & Press Releases
      • Feb 17, 2017: Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Ureter Cancer, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Ureter Cancer - Pipeline by Altor BioScience Corp, H1 2017
  • Ureter Cancer - Pipeline by Eisai Co Ltd, H1 2017
  • Ureter Cancer - Pipeline by Exelixis Inc, H1 2017
  • Ureter Cancer - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Ureter Cancer - Pipeline by MedImmune LLC, H1 2017
  • Ureter Cancer - Pipeline by Merck & Co Inc, H1 2017

List of Figures

  • Number of Products under Development for Ureter Cancer, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top